Samer Choucair: Physical Therapy Robots Are Repricing Healthcare and Creating a New Market for Capital
Investment pioneer Samer Choucair said medical rehabilitation robotics entered a new phase in 2026, evolving from mechanical devices designed primarily to assist patient movement into intelligent systems capable of learning from therapists and adjusting force, resistance, and support in real time.
Choucair said this transformation is reshaping the economics of physical therapy by increasing treatment intensity, expanding the potential for home-based rehabilitation, and turning therapist shortages into a structural catalyst for investment in automation. Market estimates valued the global rehabilitation robotics sector at approximately $1.5 billion to $2.1 billion in 2025, with projections suggesting it could grow to several billion dollars during the early 2030s. The smart rehabilitation exoskeleton market alone was estimated at around $507 million, with some growth scenarios placing it near $2.7 billion by 2032.
According to Samer Choucair, value is no longer concentrated in the motor, frame, or mechanical architecture of the device. Increasingly, the real investment value lies in a system’s ability to convert movement data into personalized rehabilitation protocols and measurable clinical outcomes.
Capital Is Following the Data, Not the Device
Samer Choucair said institutional investors are beginning to view rehabilitation robotics as part of the broader rise of “physical AI” in healthcare rather than simply as another category within the medical-device industry.
The companies attracting the greatest investor interest, Choucair said, are those combining long-term clinical data, regulatory approvals, and established distribution relationships with hospitals, healthcare networks, and insurers.
“The device on its own can become a commodity exposed to price competition,” Choucair said. “But a platform that connects a home rehabilitation session to the electronic health record and predicts the patient’s recovery trajectory becomes an asset that can be repriced through software and recurring subscription revenue.”
Investment opportunities now extend across rehabilitation exoskeletons, upper-limb robotic systems, home rehabilitation platforms, motion-capture software, remote-care services, and critical manufacturing components such as actuators, force sensors, and lightweight materials.
Robotics Is Reshaping the Economics of Rehabilitation Clinics
Samer Choucair said robots are not replacing therapists, but they are changing the production model inside rehabilitation clinics.
Highly repetitive exercises can increasingly be delegated to machines, while diagnosis, clinical judgment, and adjustments to the treatment plan remain under the control of trained professionals.
Choucair said this shift could place additional pressure on smaller clinics that lack the financial capacity to fund capital-intensive technology. Larger hospital networks and rehabilitation operators, by contrast, may be able to improve asset utilization and increase the number of patients treated per therapist.
Clinical systems range in price from tens of thousands of dollars for wearable exoskeletons to hundreds of thousands of dollars for advanced gait-rehabilitation platforms. Some sector estimates indicate that approximately 12,000 smart rehabilitation exoskeleton units were produced in 2025, with average pricing of around $43,000 under certain industry assumptions.
Saudi Arabia Could Shift From Import Market to Innovation Testbed
Samer Choucair said Saudi Arabia has an opportunity to establish a leading position in the sector, supported by Vision 2030 priorities focused on healthcare transformation, digitalization, and the localization of medical-device manufacturing.
Announced investment across the Kingdom’s healthcare-transformation ecosystem has exceeded SAR 133 billion in the context of recent partnerships and major industry events, alongside the continued expansion of virtual healthcare and robotic surgery.
Prosperity7, the investment arm backed by Saudi Aramco, has also invested in Fourier Intelligence, a company specializing in neurorehabilitation robotics, as the business expands its ambitions in the Saudi market.
Choucair said Saudi Arabia’s strategic advantage lies in combining the purchasing power of major healthcare institutions with the potential to establish a domestic manufacturing base. He cautioned, however, against reducing the investment thesis to the acquisition of machines.
“A successful institutional investment asks how many hours a day the device is being used, whether healthcare professionals have been properly trained, and whether the data are integrated into the insurance and reimbursement system,” Choucair said. “Without that loop, technology risks becoming an underutilized fixed asset.”
The Opportunity Is in the Platform, Not the Machine
Samer Choucair said the most attractive opportunities are likely to emerge in remote rehabilitation, lower-cost exoskeletons, outcomes-measurement software, and the management of robotic fleets across hospitals and rehabilitation networks.
He also expects increasing merger and acquisition activity between traditional medical-device manufacturers and healthcare software companies as value moves from standalone hardware toward integrated data and service platforms.
At the same time, Choucair warned investors to monitor regulatory and safety risks, weak insurance reimbursement, fragmented technology ecosystems, and excessive enthusiasm surrounding artificial intelligence before companies can demonstrate credible clinical outcomes.
Demographics should remain a powerful structural driver of demand, particularly as populations age and the incidence of strokes and neurological injuries continues to support long-term rehabilitation needs.
Choucair said the long-term investment thesis should therefore not be based on “everything that carries the word robot,” but on companies that control valuable clinical data, maintain strong relationships with payers, and possess credible manufacturing or distribution capabilities.
According to Samer Choucair, the real winner in this market will not necessarily be the company that builds the most sophisticated robot.
It will be the company that turns robotics into a productivity platform — making every hour of therapy more valuable and every unit of invested capital more productive.